Abstract:Background Incretin-based therapies provide additional options for treating type 2 diabetes. We aimed to evaluate the efficacy and tolerability of exenatide monotherapy in obese patients with type 2 diabetes. Methods A 26-week, metformin controlled, parallel-group study was conducted among antidiabetic drug-naive obese patients aged >18 years, and with type 2 diabetes. Participating patients were randomly assigned to receive exenatide or metformin treatments. Results Fifty-nine patients (age (50.5 +/- 8.6) years, body mass index (BMI) (30.2 +/- 1.6) kg/m(2), and hemoglobin A1C (HbA(1C) (8.2 +/- 1.2)%) were enrolled in the study. Glucose control and weight reduction improved in both groups receiving treatment. HbA(1C) and oral glucose tolerance test (OGTT) 2 hour glycemia reduction with exenatide was superior to that obtained with metformin ((-2.10 +/- 1.79)% vs. (-1.66 +/- 1.38)%, (-5.11 +/- 2.68) mmol/L vs. (-2.80 +/- 2.70) mmol/L, P <0.05). Fast plasma glucose (FPG) reduction was not significantly different between the two groups ((-1.8 +/- 2.0) mmol/L vs. (-1.6 +/- 1.7) mmol/L, P >0.05). Patients treated with exenatide achieved HbA(1C) of <7% (97% of patients) and <6.5% (79%) at end-point, vs. 93% and 73% with metformin (P >0.05). Greater weight reduction was also achieved with exenatide ((-5.80 +/- 3.66) kg) than with metformin ((-3.81 +/- 1.38) kg, P <0.01). Homeostasis model assessment of beta-cell function (HOMA-B) was not significantly increased, but the insulinogenic index and HOMA for insulin sensitivity (HOMA-S) were greatly improved in the exenatide group (P <0.05). Nausea was the most common adverse effect in exenatide treatment (30% vs. 8%; P <0.05), but most cases were of mild to moderate intensity. One case in the exenatide group was withdrawn early because of severe nausea. Hypoglycemia events were often observed during the first 4 weeks, with 12% of patients in the exenatide and 3.2% in metformin groups, respectively (P <0.05). No incidents of severe hypoglycemia were reported. Conclusions Exenatide demonstrated more beneficial effects on HbA(1C), weight reduction and insulin resistance during 26 weeks of treatment, but there were more hypoglycemic events and mild-to-moderate nausea compared with metformin. These results suggested that exenatide monotherapy may provide a viable treatment option in newly developed type 2 diabetes. Chin Med J 2012;125(15):2677-2681

Effect of Baseline -Cell Function on Treatment Response to Exenatide in Patients with Newly Diagnosed Type 2 Diabetes

966-P: Effect of Baseline SS-Cell Function on Treatment Response to Exenatide in Patients with Newly Diagnosed Type 2 Diabetes

Impact of Baseline BMI on Glycemic Control and Weight Change with Exenatide Monotherapy in Chinese Drug-naïve Type 2 Diabetic Patients.

Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus

Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.

2106-P: Glucagon-Like Peptide-1 Receptor Agonist Exenatide Promotes ß-Cell Function via Activation of PPARd/UCP-2 Pathway

Comparison of the Effects on Glycaemic Control and Β‐cell Function in Newly Diagnosed Type 2 Diabetes Patients of Treatment with Exenatide, Insulin or Pioglitazone: a Multicentre Randomized Parallel‐group Trial (the CONFIDENCE Study)

Comparison of Changes in Adipokine and Inflammatory Cytokine Levels in Patients with Newly Diagnosed Type 2 Diabetes Treated with Exenatide, Insulin, or Pioglitazone: a Post-Hoc Study of the CONFIDENCE Trial

745-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Insulin Sensitivity in Type 1 Diabetes

Comparing the Effects of Twice-Daily Exenatide and Insulin on Renal Function in Patients with Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Controlled Trial.

The Effects of Exenatide and Metformin on Endothelial Function in Newly Diagnosed Type 2 Diabetes Mellitus Patients: A Case–Control Study

962-P: Impacts of Different Hypoglycemic Agents on Adipokines and Inflammatory Markers in Newly Diagnosed T2D Patients

Exenatide Treatment Decreases Fasting Fibroblast Growth Factor 21 Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.

Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes

The Factors Influencing The Changes Of Adipocytokines In Patients With Newly Diagnosed T2dm Treated With Exenatide

Long-term efficacy and tolerability of exenatide treatment in patients with type 2 diabetes

Cost-Effectiveness Analysis of Exenatide Twice Daily (BID) Versus Insulin Glargine Once Daily (QD) As Add-on Therapy in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled by Oral Therapies.

High Baseline FGF21 Levels Are Associated with Poor Glucose-Lowering Efficacy of Exenatide in Patients with Type 2 Diabetes

Efficacy and Safety of Exenatide in Patients of Asian Descent with Type 2 Diabetes Inadequately Controlled with Metformin or Metformin and a Sulphonylurea

Effects of Exenatide Versus Insulin Glargine on Body Composition in Overweight and Obese T2DM Patients: a Randomized Controlled Trial

Evaluation of the Curative Effect of Exenatide and Insulin Detemir on the Treatment of Type 2 Diabetes by Continuous Glucose Monitoring System